Slide 1: Ipca Laboratories Ltd. Corporate Presentation
Ipca Laboratories Ltd. Corporate Presentation June 2023 1
Slide 2: Company Overview
Company Overview Incorporation : 1949 Present Management : Since 1975 Total income F. Y. 2022-23 : Rs. 5925.81 Crs / US$ 739 Mn (Standalone) Rs. 6369.94 Crs / US$ 794 Mn (Consolidated) Exports F. Y. 2022-23 : Rs. 2643.42 Crs / US$ 330 Mn Business Model : Integrated pharmaceutical company producing B
Slide 3: Five Years' Highlights - Standalone
Five Years’ Highlights Standalone 2018-19 2019-20 2020-21 2021-22 2022-23 Domes tic Income ( R s . C rs ) 1,956.90 2,288.37 2,484.21 2,983.09 3,282.39 Domes tic Income (US $ Mn) 276.24 323.03 333.94 400.58 409.17 E xport Income ( R s . C rs ) 1,730.84 2,143.75 2,717.19 2,508.13 2,643.42 E xport Inco
Slide 4: Five Years' Highlights - Consolidated
Five Years’ Highlights Consolidated 2018-19 2019-20 2020-21 2021-22 2022-23 Domes tic Income ( R s . C rs ) 1,956.90 2,327.88 2,519.77 3,077.75 3,391.07 Domes tic Income (US $ Mn) 276.24 328.61 338.72 413.29 422.72 E xport Income ( R s . C rs ) 1,873.96 2,387.83 2,963.06 2,818.61 2,978.87 E xport In
Slide 5: Manufacturing Facilities - Formulations
Manufacturing Facilities Formulations 5
Slide 6: Manufacturing Facilities - Formulations
Manufacturing Facilities Formulations Location Dosage Form Approvals / Inspections UK-MHRA, TGA-Australia, WHO-Geneva, EU Certification by German Authority, Health Canada, GCC, MOH- Athal Columbia, FDA Ghana, MOH Oman, NDA - Uganda, NHRA (Dadra & Nagar Tablets & Capsules – Bahrain, Medicine and Drug
Slide 7: Manufacturing Facilities - Formulations
Manufacturing Facilities Formulations Location Dosage Form Approvals / Inspections Silvassa WHO-cGMP, TGA-Australia, Health- Tablets & Capsules (Dadra & Nagar Haveli) Canada, Local FDA Unit - I : GMP under Schedule M (CDSCO+FDA), GMP & GLP (FDA Uttarakhand) Dehradun, Tablets & (Uttarakhand) Cephalos
Slide 8: Manufacturing Facilities - APIs
Manufacturing Facilities Active Pharmaceutical Ingredients (APIs) 8
Slide 9: Manufacturing Facilities - APIs
Manufacturing Facilities APIs Location Approvals / Inspections TGA-Australia, EDQM, PMDA-Japan, WHO-Geneva, Health Canada, EU-GMP (LaGesso, Berlin), MOH Russia, Ratlam (Madhya Pradesh) MFDS (Korea), CDSCO- India, Cofepris (Mexico), EU WC, ANVISA (Brazil) Indore (Madhya Pradesh) WHO-Geneva, CDSCO- In
Slide 10: Revenue Break-up
Revenue Break-up 10
Slide 11: Revenue Break-up - Standalone
Revenue Break-up - Standalone 2022 - 23 24% Formulations Domestic Total 45% Total Revenue 55% API Exports 76% 12% 38% Formulations Formulations Exports Domestic 62% API API 88% 11
Slide 12: Revenue Break-up Standalone
Revenue Break-up Standalone 2022--23 2021-22 Rs. Crs Domestic Exports Total Domestic Exports Total Growth Branded Formulations 2760.71 504.79 3265.50 2508.27 415.99 2924.26 11.7% Generic/ Institution/ Tender Formulations - 1134.40 1134.40 - 1070.75 1070.75 5.9% Total Formulations 2760.71 1639.19 439
Slide 13: Financials
S£ipca dose of life Financials
Slide 14: Financials - Standalone FY 2022-23
Financials - Standalone F .Y. 2022 - 23 F .Y. 2021 - 22 % R s . C rs US $ Mn R s . C rs US $ Mn G rowth T otal Inc ome 5925.81 739 5491.22 737 8% E B IDT 1054.05 131 1259.52 169 -16% E B IDT % 17.79% 22.94% PBT # 750.49 94 1074.11 144 -30% PBT % 12.66% 19.56% P AT # 505.70 63 860.37 116 -41% P AT %
Slide 15: Financials - Standalone Profitability
Financials - Standalone Profitability F Y 2022-23 F Y 2021-22 P B IDT 17.79% 22.94% PBT 12.66% 19.56% P AT 8.53% 15.67% 15
Slide 16: Financials - Standalone Business Characteristics
Financials - Standalone Business Characteristics FY 2022-23 FY 2021-22 Return on Capital Employed % (PBIT / Capital Employed) 11.59% 17.85% Return on Net Worth % (PAT / Net Worth) 8.60% 15.71% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.28 2.24 Capital Employed Turnover Ratio (Tot
Slide 17: Financials - Standalone Growth
Financials - Standalone G rowth F Y 2022-23 F Y 2021-22 Net Total Income 7.9% 4.9% Domes tic S ales 9.3% 19.7% E xport S ales 5.4% -7.9% P B IDT -16.3% -17.4% PBT -30.1% -21.1% Net P rofit -41.2% -23.7% 17
Slide 18: Financials - Standalone Q1 FY24
Financials - Standalone Q1 FY24 Q1 FY23 % Rs. Crs US$ Mn Rs. Crs US$ Mn Growth Total Income 1531.87 186 1496.24 193 2% EBIDT 284.08 35 269.27 35 6% EBIDT % 19.08% 18.21% PBT # 249.58 30 211.39 27 18% PBT % 16.76% 14.30% PAT # 166.58 20 140.07 18 19% PAT % 11.19% 9.47% # After forex gain of Rs. 13.45
Slide 19: Financials - Consolidated FY 2022-23
Financials - Consolidated F .Y. 2022 - 23 F .Y. 2021 - 22 % R s . C rs US $ Mn R s . C rs US $ Mn G rowth T otal Inc ome 6369.94 794 5896.36 792 8% E B IDT 1083.77 135 1345.04 181 -19% E B IDT % 17.01% 22.81% PBT # 745.29 93 1135.72 153 -34% PBT % 11.70% 19.26% P AT # 471.32 59 884.08 119 -47% P AT
Slide 20: Financials - Consolidated Business Characteristics
Financials - Consolidated Business Characteristics FY 2022-23 FY 2021-22 Return on Capital Employed % (PBIT / Capital Employed) 15.21% 18.65% Return on Net Worth % (PAT / Net Worth) 10.58% 15.95% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.92 2.18 Capital Employed Turnover Ratio (
Slide 21: Financials - Consolidated Growth
Financials - Consolidated G rowth F Y 2022-23 F Y 2021-22 Net Total Income 8.0% 7.5% Domes tic S ales 9.5% 22.7% E xport S ales 5.7% -4.9% P B IDT -19.4% -14.1% PBT -34.4% -18.2% Net P rofit -46.7% -22.4% 21
Slide 22: Financials - Consolidated Q1 FY24
Financials - Consolidated Q1 FY24 Q1 FY23 % Rs. Crs US$ Mn Rs. Crs US$ Mn Growth Total Income 1632.43 199 1607.85 208 2% EBIDT 294.13 36 283.46 37 4% EBIDT % 18.53% 17.88% PBT # 251.82 31 222.69 29 13% PBT % 15.86% 14.04% PAT # 162.82 20 143.06 18 14% PAT % 10.26% 9.02% # After forex gain of Rs. 13.
Slide 23: Contribution of Therapeutic Groups
Financials - Standalone Contribution of Therapeutic Groups Domes tic E xports Therapeutic S egment 2022-23 2021 – 22 2022-23 2021 – 22 Non S teroidal Anti-Inflammatory Drugs 52% 49% 28% 24% (NS AID) C ardiovas culars & Anti-Diabetics 16% 17% 24% 25% Anti-B acterials 6% 7% 6% 6% Anti-Malarials 3% 5%
Slide 24: Branded Formulations - Domestic
Branded Formulations Domestic 24
Slide 25: Branded Formulations Domestic
Branded Formulations Domestic All India Rank IQVIA : 17th (MAT June’23). 24 Depots & 1 C&F agents. 21 Therapy Focused Marketing Divisions. Field Strength (PSR/ BA)– 6180 Over 4000 Wholesalers. 5 brands among top 300 brands (Zerodol-SP, Zerodol-P, HCQS, Folitrax & Zerodol TH). Market leaders in Rheum
Slide 26: Branded Formulations Domestic Sales
Branded Formulations Domestic Rs. 2760.71 Crs Rs. 2508.27 Crs US $ 344 Mn US $ 337 Mn Rs. 1912.61 Crs Rs. 1981.67 Crs US$ 270 Mn US$ 266 Mn Sales 2019-20 2020-21 2021-22 2022-23 26
Slide 27: Branded Formulations Future Growth Drivers
Branded Formulations Domestic Future Growth Drivers Clinical research as a tool to launch innovative combination formulations / NDDS. Strong Brand building with focused promotion. In licensing/ out licensing to build business in the promoted therapy. Portfolio optimization, strategies to identify ne
Slide 28: International Business
S£ipca dose of life International Business
Slide 29: International Business
International Business Products of the company are now exported to over 100 countries across the globe. Recognized Star Trading House. 41% sales from exports. Field-force to promote brands in more than 35 countries of CIS, South East Asia, Middle East, Latin America and Africa. 29
Slide 30: International Business Marketing Offices
International Business Marketing offices in Russia, Ukraine, Kazakhstan, Belarus , Vietnam, Philippines, Sri Lanka, Myanmar Kenya, Colombia, and Nigeria & Mexico (subsidiary company). Formulation dossiers for branded formulations registered in 58 countries. 30
Slide 31: International Business Sales
International Business Rs. 2717.19 Crs Rs. 2643.42 Crs Rs. 2508.13 Crs US$ 365 Mn US $ 330 Mn US$ 337 Mn Rs. 2143.75 Crs US$ 303 Mn Sales 2019-20 2020-21 2021-22 2022-23 31
Slide 32: Continent-wise Exports 2022-23
International Business C ontinent-wis e E xports 2022 –23 (R s . C rs ) B ulk Drugs / % C ontinent Formulations Intermediates Total C ontribution E urope 486.11 273.53 759.64 29% Africa 416.76 55.05 471.81 18% Americas 163.17 297.79 460.96 17% As ia 110.82 341.52 452.34 17% C IS 188.44 32.53 220.97
Slide 33: International Formulations
International Formulations 33
Slide 34: International Formulations Sales
International Formulations Rs. 1597.19 Crs Rs. 1639.19Crs US$ 215 Mn Rs. 1486.74 Crs US $ 204 Mn US $ 200 Mn Rs. 1221.55 Crs US$ 172 Mn Sales 2019-20 2020-21 2021-22 2022-23 34
Slide 35: International Branded Formulations
International Branded Formulations 35
Slide 36: International Branded Formulations Sales
International Branded Formulations Rs. 504.79 Crs US$ 63 Mn Rs. 415.99 Crs Rs. 403.42 Crs Rs. 381.53 Crs US $ 56 Mn US$ 54 Mn US$ 54 Mn Sales 2019-20 2020-21 2021-22 2022-23 36
Slide 37: International Future Growth Drivers
International Branded Formulations Future Growth Drivers Thrust on brand building in Pain, CVS, CNS, Anti-infective and Anti-malarial segments. Geographical expansion in covered countries through additional field force. Expansion in business lines - Institutions and Distributors. Introduction of new
Slide 38: International Generics/Institution/Tender
International Generics/ Institution/ Tender 38
Slide 39: Generics/Institution/Tender Sales
International Generics/ Institution/ Tender Sales Rs. 1193.77 Crs Products US$ 160 Mn Rs. 1134.40 Crs Products Rs. 1070.75 Crs Country Under US$ 141 Mn Registered US $ 144 Mn Registration Rs. 840.02 Crs US$ 119 Mn United Kingdom 92 6 / Europe Australia / 73 3 New Zealand South Africa 52 11 United St
Slide 40: Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. Formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements. Future G
Slide 41: International APIs
S£ipca dose of life International APIs
Slide 42: APIs Sales
International APIs Rs. 1120.00 Crs Rs. 1004.23 Crs Rs. 1021.39 Crs Rs. 922.20 Crs US$ 151 Mn US$ 125 Mn US $ 137 Mn US$ 130 Mn Sales 2019-20 2020-21 2021-22 2022-23 42
Slide 43: APIs - Drug Master Files
International APIs – Drug Master Files S r. US - C anada- J apan - No. Name of the AP I F DA HP F B WHO P MDA Aus tralia E DQM 1 Alendronate S odium a a a 2 Allopurinol a a CEP a 3 Amlodipine B es ylate a a 4 Amodiaquine Hcl a 5 Artemether a a 6 Artes unate a 7 Artes unate S terile a 8 Atenolol a a
Slide 44: APIs - Drug Master Files
International APIs – Drug Master Files S r. US - C anada- J apan - No. Name of the AP I F DA HP F B WHO P MDA Aus tralia E DQM C etrizine Hydrochloride (C Z5/ 16 C Z6 P roces s ) a CEP a 17 C hloroquine P hos phate a a 18 C hlorthalidone (C T 3/C T 7 P roces s ) a a a 19 C hlorthalidone (C T 6 P roc
Slide 45: APIs - Drug Master Files
International APIs – Drug Master Files S r. US - C anada- J apan - No. Name of the AP I F DA HPF B WHO P MDA Aus tralia E DQM 31 G limepiride a a a 32 Hydrochlorothiazide (P roces s I) a a a CEP a 33 Hydrochlorothiazide (P roces s II) a a 34 Hydrochlorothiazide (P roces s III) a 35 Hydroxychloroquin
Slide 46: APIs - Drug Master Files
International APIs – Drug Master Files S r. US - C anada- J apan - No. Name of the AP I F DA HPF B WHO PMDA Aus tralia E DQM 46 Metformin HC L (ML P roces s ) a 47 Metformin HC L (ML 2 P roces s ) a a CEP a 48 Methylphenidate HC L a CEP a 49 Metoclopramide B as e a 50 Metoclopramide HC l CEP a 51 Me
Slide 47: APIs - Drug Master Files
International APIs – Drug Master Files S r. US - C anada- J apan - No. Name of the AP I FDA HP F B WHO P MDA Aus tralia E DQM 61 Paroxetine Hcl CEP a 62 Piperaquine Phosphate a 63 Primaquine Phosphate a a 64 Probenecid a 65 Proguanil Hydrochloride a a 66 Promethazine Hydrochloride a 67 Propranolol H
Slide 48: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 76 Telmisartan (WT3A Process) a 77 Torsemide a a 78 Tramadol Hydrochloride a Tramadol Hydrochloride (YT2 79 Process) a Tramadol Hydrochloride (YT3 80 Process) a a 81 Triamterene a a 82
Slide 49: APIs - Drug Master Files
International APIs – Drug Master Files S r. US - C anada- J apan - No. Name of the AP I FDA HP F B WHO P MDA Aus tralia E DQM 91 Hydroxyzine Pamoate a 92 Meloxicam a a Total 55 23 7 14 20 57 Note : Aus tralia accept C E P is s ued by E DQM 49
Slide 50: APIs Future Growth Drivers
International APIs Future Growth Drivers Consolidate API business of Sartans across the globe. Long term strategic tie-ups with major South American/European formulators. Leverage the customer base of more than 1000 customers spread across 90 countries is well laid down platform to introduce Ipca ne
Slide 51: Research & Development
Research & Development APIs & Formulations 51
Slide 52: Research & Development Spending
Research & Development APIs & Formulations R & D Spending Year Rs. Crs % to Sales 2018-19 89.35 2.50% 2019-20 101.04 2.35% 2020-21 126.67 2.49% 2021-22 141.46 2.63% 2022-23 156.49 2.71% 52
Slide 53: Research & Development
Research & Development APIs & Formulations Current scientist manpower of around 564 Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 248 patent applications filed. Bio-tech / fermentatio
Slide 54: Inception of Advanced Biotech Lab
Inception of Advanced Biotech Lab (Biosimilar R&D) Established “State of the Art” R&D in 2015 Lashed with modern equipments and HTP devices Capable of In-house Development from “Clone to Commercialization” Single-use Manufacturing Facility (DS+DP-cGMP) to be Ready by Dec., 2023 Scientific Staff : 70
Slide 55: Biosimilar Pipelines
Biosimilar Pipelines Molecules: Anti-cancer and Anti-inflammatory mAbs 6 monoclonal antibodies (mAbs) at various stage of the development Target markets India, UK, EU, ROW followed by USA Sought EMA and MHRA-UK Scientific Advice for mAb1 & mAb2 Three Biosimilars in the Market (India)-P2P Open for th
Slide 56: Thank you
Thank you No part of this corporate presentation may be re-produced, quoted or circulated without prior approval of Ipca Laboratories Limited. This presentation may include forward looking statements based on our current business expectations. Our actual results may differ from what is projected in